SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Lesofavumab

Cat. No.:	HY-P99699
CAS No.:	1807960-57-1
Target:	Influenza Virus
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Lesofavumab (MHAB5553A) is a human IgG1κ anti-influenza B virus antibody[1].
IC_{50} & Target	Influenza B virus[1]
In Vitro	Lesofavumab (MHAB5553A) binds to a conserved epitope in the vestigial esterase domain of hemagglutinin (HA), a major immunodominant surface glycoprotein on influenza B viruses, and blocks HA-mediated membrane fusion in the endosome [1]. Lesofavumab (46B8) is able to neutralize all eleven IBV strains tested that were associated with human infections spanning >70 years, with IC_{50} values ranging from 0.58 to 0.95 nM[2]. Lesofavumab (46B8; 0-100 ng/mL) blocks membrane fusion and induces antibody-dependent cellular cytotoxicity (ADCC) in vitro[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Lesofavumab (46B8; 15 mg/kg; i.v.; single dose) is able to protect mice against lethal challenge of the mutant influenza B virus[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	DBA/2 J mice, B/Wisconsin/1/2010, B/Brisbane/60/2008, B/Victoria/504/2000, B/Russia/1/1969 or B/Massachusetts/3/1966 infection model[2]
Dosage:	15 mg/kg
Administration:	Intravenous administration, single dose, 24, 48 or 72 h post infection
Result:	Treatment at 24 and 48 h post infection resulted in 100% protection, with the only exception of mice infected with B/Russia/1/1969 that showed a 60% protection when treatment commenced at 48 h. Even when given at 72 h post infection, 48B8 was highly efficacious resulting in 100% protection against the B/Brisbane/60/2008, B/Victoria/504/2000 and B/Massachusetts/3/1966 strains, 75% protection against B/Wisconsin/1/2010 and 50% protection against B/Russia/1/1969.

REFERENCES

[1]. Rao GK, et al. In Vivo Assessment of Antibody-Dependent Enhancement of Influenza B Infection. Toxicol Sci. 2019 Jun 1;169(2):409-421.

[2]. Chai N, et al. A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Nat Commun. 2017 Jan 19;8:14234.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA